Stryker Co. (NYSE:SYK) Holdings Raised by Arizona State Retirement System

Arizona State Retirement System lifted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 99,215 shares of the medical technology company's stock after purchasing an additional 911 shares during the period. Arizona State Retirement System's holdings in Stryker were worth $35,722,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the fourth quarter worth about $25,000. Dunhill Financial LLC raised its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after acquiring an additional 37 shares during the period. Centricity Wealth Management LLC acquired a new stake in Stryker during the fourth quarter worth about $30,000. BankPlus Trust Department acquired a new stake in Stryker during the fourth quarter worth about $33,000. Finally, Darwin Wealth Management LLC acquired a new stake in Stryker during the third quarter worth about $36,000. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Remove Ads

Stryker Price Performance

Shares of NYSE SYK traded down $3.03 during mid-day trading on Friday, reaching $379.28. 1,961,830 shares of the company traded hands, compared to its average volume of 1,209,637. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market cap of $144.73 billion, a PE ratio of 48.88, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The stock has a fifty day simple moving average of $382.45 and a 200-day simple moving average of $372.99.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business earned $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on SYK shares. JPMorgan Chase & Co. increased their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Citigroup reiterated a "buy" rating and set a $450.00 price objective on shares of Stryker in a research note on Wednesday, February 26th. Morgan Stanley upgraded shares of Stryker from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Barclays raised their price target on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Finally, Truist Financial raised their price target on shares of Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.